Opendata, web and dolomites

Sencell16

Lifecare’s Sencell sensor is an implantable micro-sensor for subcutaneous location, long time, continuous, wireless, real time monitoring of interstitial glucose for diabetes management.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Sencell16 project word cloud

Explore the words cloud of the Sencell16 project. It provides you a very rough idea of what is the project "Sencell16" about.

autonomously    proprietary    entire    cavity    located    warning    hypoglycemia    generate    induce    encased    transmitter    patented    automatically    membrane    device    wires    fluid    function    arm    inside    substances    biocompatible    independently    translates    improves    subcutaneous    inner    interstitial    contains    concanavalin    operation    influence    covered    doses    sensor    enclosed    permeable    protruding    subcutaneously    monitoring    glucose    accurate    insulin    cell    utilizes    mobile    final    blood    space    wrist    sites    significantly    signals    relayed    time    osmotic    noninvasively    semi    physical    sensors    places    insertion    body    alternatives    medical    battery    sugar    pressure    user    intended    transducer    prompting    unlike    longer    reading    communication    reducing    enzymatic    material    implanted    miniaturized    signal    designed    skin    suitable    sensitivity    core    cona    dextran    hyperglycemia    sencell   

Project "Sencell16" data sheet

The following table provides information about the project.

Coordinator
LIFECARE AS 

Organization address
address: OVRE KRAKENES 17
city: BERGEN
postcode: 5152
website: www.lifecare.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://www.lifecare.no
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIFECARE AS NO (BERGEN) coordinator 50˙000.00

Map

 Project objective

The SENCELL Glucose Monitoring System includes an osmotic pressure sensor, transmitter and mobile medical application. The miniaturized sensor is designed to be implanted into the subcutaneous space of arm wrist or other suitable body sites and requires no battery or wires for the sensor operation and for communication with the transmitter. After insertion, the sensor is designed to function noninvasively, automatically, and continuously for a long term duration that is comparable or longer than existing product alternatives.

The miniaturized SENCELL is designed to continuously measure glucose in the interstitial fluid for a long term duration that is comparable or longer than existing product alternatives. Unlike currently used glucose sensors, the Sencell is intended to be implanted subcutaneously on the arm wrist or other subcutaneous places in the body with no sensor part protruding from the skin.

Encased in a biocompatible material, the device utilizes a unique osmotic pressure assessment technology, which translates the signal of a physical miniaturized osmotic pressure cell into an accurate glucose reading that can be used for determination of insulin doses and to generate warning signals in case of hypoglycemia or hyperglycemia development.

The inner core of the device is the unique and proprietary osmotic patented pressure cell, which is covered on one side by a semi-permeable membrane. The membrane is enclosed inside the top of a cavity where the pressure transducer is also located. The cavity contains Concanavalin A and Dextran.

The use of ConA/Dextran as enzymatic component significantly improves the sensitivity to changes in the blood sugar level while reducing the influence from other substances in the blood. In the final product, the measurement is then relayed to the transmitter. The entire measurement is designed to be done autonomously and independently without any prompting by the user. However, the user can induce a measurement at any time

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENCELL16" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENCELL16" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More